NFE2L2 and Friedreich ataxia: Recently, the FDA approved omaveloxolone, a potent activator of Nrf2 signaling, as the first therapeutic agent for FRDA (392), marking a significant step toward targeting redox imbalance and ferroptosis in this disease.